AddedRisk Factors
In the United States, federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of healthcare and addressing public concern over access and affordability of prescription drugs. The Affordable Care Act (ACA) made significant changes to the U.S. healthcare system, which included expanding healthcare coverage through Medicaid and implementation of the individual health insurance mandate; changing coverage and reimbursement of drug products under Medicare, Medicaid and 340B government programs; imposing an annual fee on manufacturers of branded drugs; and expanding government enforcement authority. Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. The One Big Beautiful Bill Act (OBBBA) has enacted, among others, changes to eligibility requirements for premium tax credits, which is expected to result in less coverage in the ACA’s health insurance marketplace (Marketplace) over the next few years. The ACA premium tax credits expired at the end of 2025, which resulted in an additional loss of coverage for an estimated 24 million people that were previously enrolled in insurance plans obtained through the Marketplace. In addition, the OBBBA has made other changes to the enrollment and eligibility requirements for Medicaid, which is expected to result in the loss of coverage for certain individuals currently enrolled in Medicaid programs. Further, The Centers for Medicare & Medicaid Services (CMS) recently proposed two mandatory payment model pilots, the Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model, focused on Part D drugs, and Global Benchmark for Efficient Drug Pricing (GLOBE), focused on Part B drugs, which will require pharmaceutical companies to pay additional rebates on certain medicines, including central nervous system agents for the treatment of multiple sclerosis, whose U.S. net-of-discount prices exceed those in certain other countries.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
Further, executive orders were signed to implement Most Favored Nation drug pricing policies designed to align certain prescription drug prices in the U.S. to lower prices available in other countries. Investigations are being conducted to examine price differentials and consider policy approaches for implementation, including through administrative action, and letters have been sent to pharmaceutical companies demanding further reduced prices more in line with Most Favored Nation pricing. If such Most Favored Nation policies are implemented, changes to drug pricing are expected to affect the profitability of pharmaceutical and biotech companies in the U.S. as well as in other countries, as a price referencing policy to the U.S. market could make it commercially unviable to commercialize a drug product in a price constrained market. The details of the proposed policies are unclear and the final terms and impact remain uncertain, and may pose long-term risks to our business and our future commercialization plans of our products and product candidates. In addition, the Fair Prescription Drug Prices for Americans Act was re-introduced in May 2025 and proposes to cap the retail list price of prescription drugs and biological products in the United States at the average retail list price for such product among certain countries. Although it is uncertain if these pricing proposals will take effect, reducing drug prices remains a bipartisan effort and, if made effective, could significantly impact coverage, pricing, and reimbursement for any approved product. These and other similar developments could significantly limit the degree of market acceptance of our products or any of our other product candidates that receive marketing authorization. We expect that healthcare reform measures that may be adopted in the future may result in increased manufactured financial liability and additional downward pressure on the price that we may receive for any of our product candidates, if approved. Any reduction in reimbursement from Medicare or other government health care programs may result in a similar reduction in payments from private payors.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
There is also a great degree of uncertainty regarding how the recent U.S. Supreme Court decisions, including Loper Bright Enterprises v. Raimondo and Corner Post, Inc. v. Board of Governors of the Federal Reserve System, will impact FDA’s enforcement and decision-making authority of regulatory agencies, including those of the FDA. Loper Bright explicitly overturned Chevron deference, which previously gave judicial deference to administrative action by agencies in the executive branch. Further, the Supreme Court’s decision in Corner Post may result in challenges to FDA decisions by new litigants long into the future, resulting in greater uncertainty about our continued operations. In February 2025, an executive order was signed asserting greater authority over all federal agencies, including those established by Congress as independent from direct presidential control. The executive order may lead to continued delays, if not cancellations, of pending and proposed regulations at federal agencies and introduces uncertainty as it subjects all significant regulatory actions by the agencies to the President’s supervision and control. We cannot predict the impact that such executive order, any future executive orders or legislation implementing executive orders may have on our business or our results of operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedRisk Factors
the federal Civil Monetary Penalties law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary’s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedRisk Factors
obtain, develop, maintain, protect, and defend our intellectual property portfolio; and
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
any shifts in the regulatory focus of the U.S. government as a reflection of changing administrations;
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
the FDA or comparable foreign regulatory authorities may identify issues related to the manufacturing processes or
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
facilities of third-party manufacturers with which we or our collaborators currently contract for clinical supplies and
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
We are currently focusing the majority of our efforts on maintaining approval, improving and commercializing BRIUMVI and developing azer-cel for particular indications. As a result, we may fail to capitalize on other indications or product candidates that may ultimately have proven to be more profitable.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
In the United States, the President, federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of healthcare and addressing public concern over access and affordability of prescription drugs. The Affordable Care Act, made significant changes to the U.S. healthcare system, which included expanding healthcare coverage through Medicaid and implementation of the individual health insurance mandate; changing coverage and reimbursement of drug products under Medicare, Medicaid and 340B government programs; imposing an annual fee on manufacturers of branded drugs; and expanding government enforcement authority. The ACA has been the subject of legislative and litigation challenges. We cannot predict whether the new U.S. administration would impose any further changes to the ACA and what effect, if any, such changes to the ACA would have on our business.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
reception and success of BRIUMVI in the German market and the anticipated launch of BRIUMVI in additional European markets;
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
We believe that climate change has the potential to negatively affect our business, results of operations, financial condition and growth prospects. The adverse impacts of climate change include (i) physical risks such as increased frequency and severity of natural disasters and extreme weather events such as hurricanes, tornados, wildfires (exacerbated by drought), flooding, and extreme heat, (ii) risks in transitioning to a low-carbon economy (such as additional legal or regulatory requirements, changes in technology, market risk and reputational risk) and (iii) social and human effects (such as population dislocations and harm to health and well-being).
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
New legal or regulatory requirements may also be enacted to prevent, mitigate, or adapt to the implications of a changing climate and its effects on the environment. These regulations, which may differ across jurisdictions, could result in our manufacturing partners being subject to new or expanded carbon pricing or taxes, increased compliance costs, restrictions on greenhouse gas emissions, investment in new technologies, increased carbon disclosure and transparency, upgrading of facilities to meet new building codes, and the redesign of utility systems, which could increase our third-party manufacturers’ operating costs, including the cost of electricity and energy used to develop our products. Our supply chain as a whole would likely be subject to these same transitional risks and would likely pass along any increased costs to us.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
We identified a material weakness in our internal control over financial reporting related to non-routine share-based payment awards, which has been remediated. If we fail to develop and maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable laws and regulations could be impaired.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
During the preparation of our unaudited condensed consolidated financial statements for the period ended June 30, 2024, we identified a material weakness in our internal control over financial reporting related to a process-level control over share-based payment awards not being designed effectively. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. To remediate the material weakness, the Company has designed and implemented additional preventative controls around non-routine share-based payment awards to ensure the appropriate recognition and measurement of such awards, and enhanced risk assessment procedures to ensure that all non-routine share-based payment awards are appropriately identified and evaluated.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedRisk Factors
Management, including our Chief Executive Officer and Chief Financial Officer, has performed testing to verify the effective design and successful operating effectiveness of the new or enhanced controls, determined that control activities have operated effectively for a sufficient period of time and concluded that the previously disclosed material weakness has been remediated as of December 31, 2024.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RewordedRisk Factors
We are also continuing to generate additional clinical data for BRIUMVI to support and potentially expand commercial adoption, including assessing long-term tolerability in our Open-Label Extension of the Phase 3 ULTIMATE I and II trials trials, Phase 3 trial to evaluate subcutaneous ublituximab, Phase 3b ENHANCE trial, the Phase 4 ENABLE real-world observational study and additional Phase 4 clinical studies necessary to satisfy post-approval commitments for regulatory authorities or those undertaken voluntarily by the Company to evaluate the use of BRIUMVI in alternate settings or with alternate methods of administration. authorities.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Moreover, we expect to continue to incur significant research and development expenses, as well as significant commercialization and outsourced manufacturing expenses as we continue to commercialize BRIUMVI over and continue to advance our clinical trials to evaluate subcutaneous ublituximab, optimize intravenous BRIUMVI for patients with RMS, and evaluate BRIUMVI in other autoimmune diseases and azer-cel for the foreseeable future. treatment of primary progressive MS.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We currently have one marketed product, BRIUMVI, which received approval from the FDA on in December 28, 2022, for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. adults, as well as approval by several regulatory authorities outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, negative or inaccurate postings or comments on social media or networking websites about the Company us or our brands brands, including as a result of collaborations with third parties, could generate adverse publicity that could damage our reputation or the reputation of our brands. brands or harm our relationships with customers, end-users, business partners, investors, or other key stakeholders.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We have adopted a code of ethics applicable to all of our employees and have implemented a compliance program, but it It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply be in compliance with these such laws or regulations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Following the change Any changes in U.S. administration, there is uncertainty regarding future U.S. regulations or policies and legislative and regulatory changes related to taxation and importation, which including as a result of increased tariffs, could adversely impact the global economy and our operating results.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Given However, due to the long lead times and cost of costs associated with establishing and qualifying additional commercial manufacturing sites sites, we expect that we will to rely on single a limited number of contract manufacturers to produce our commercial products under current Good Manufacturing Practice, or cGMP, regulations for the next several years. foreseeable future.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
The California Privacy Rights Act of 2020 (CPRA) significantly expanded the CCPA to grant additional rights to California residents and established a new California data privacy protection agency is authorized to issue substantive regulations and that could result in increased privacy and information security enforcement.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we do not accurately evaluate the commercial potential or target markets for a particular BRIUMVI and our other product candidate, candidates, we may relinquish valuable rights to that our product candidate candidates or programs through strategic collaboration, licensing, sale or other strategic arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. candidates or programs.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Furthermore, the United States and its European allies other countries have imposed significant sanctions against Russia and Belarus, including regional embargoes, full blocking sanctions, and other restrictions targeting major from doing business with certain Russian companies and financial institutions.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We have established a contract manufacturing relationship with Samsung Biologics for the our primary clinical and commercial supply of BRIUMVI BRIUMVI, and a secondary contract manufacturing relationship with Samsung Biologics. FUJIFILM Diosynth Biotechnologies.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
We Further, we may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful. unsuccessful for which it would have been more advantageous to enter into a partnering arrangement.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If we or others identify unexpected side effects or adverse events caused by BRIUMVI or other products or product candidates within the RMS space following introduction into the market, a number of potentially significant negative consequences could result, including:
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We have incurred significant substantial operating losses since our inception, and we may incur losses in the future.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
For the foreseeable future, we will have to fund all our operations and capital expenditures from sales of BRIUMVI, cash on hand and amounts raised in future offerings or financings.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that may have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
A positive primary endpoint does may not translate to all, or any, secondary endpoints being met.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Our product or product candidates may cause undesirable side effects or adverse events that could delay or prevent their regulatory approval or impact their availability and commercial potential after approval.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If our contract manufacturers cannot do not successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others and the compliance concerns cannot be resolved, remediated, or otherwise addressed to the FDA’s or others’ satisfaction in a timely manner during the review of any marketing applications that we submit, it may negatively impact our ability to obtain regulatory approval for our drug candidates or obtain approval within projected timelines.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody indicated for the treatment of relapsing forms of multiple sclerosis (RMS), was approved by the U.S. Food and Drug Administration (FDA) in December 2022 and commercially launched in the United States in January 2023. BRIUMVI is administered as a one-hour, twice per year infusion following the starting dose. Since launch, our commercialization efforts have focused on expanding prescriber awareness, increasing penetration across infusion centers and neurology practices, securing payer coverage, and supporting patient access within a competitive RMS treatment landscape.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
We believe BRIUMVI’s clinical profile, including its one-hour infusion time and twice-annual dosing schedule, together with demonstrated efficacy and safety in pivotal trials and accumulating real-world experience, supports its positioning within the anti-CD20 therapeutic class. The anti-CD20 class represents a significant segment of the RMS market, reflecting physician familiarity with the mechanism of action and long-term treatment considerations. Our ability to expand adoption is dependent on continued execution across access and site-of-care pathways; however, uptake may be influenced by factors including established prescribing practices, patient switching dynamics, payer coverage and utilization management requirements, competitive contracting, site-of-care logistics, and evolving treatment guidelines.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In August 2023, we entered into a Commercialization Agreement with Neuraxpharm Pharmaceuticals, S.L. (Neuraxpharm), pursuant to which Neuraxpharm obtained rights to commercialize BRIUMVI outside the United States. Under the agreement, we are eligible to receive milestone payments, royalties and revenue from product supply to Neuraxpharm. The timing and magnitude of ex-U.S. revenues depend on country-specific regulatory approvals, pricing and reimbursement determinations, launch timing, and commercial uptake. We provide development, regulatory, and other support services as required under the agreement to facilitate commercialization activities in applicable territories.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
The RMS market is highly competitive and includes numerous approved disease-modifying therapies with varying mechanisms of action, routes of administration, safety profiles, and dosing schedules. Competitive dynamics may be influenced by pricing and contracting strategies, payer utilization management practices, the introduction of new branded products or biosimilars, and broader healthcare system and macroeconomic conditions. Our ability to continue to grow BRIUMVI revenues will depend on sustained physician adoption, patient persistence and adherence, competitive differentiation within the anti-CD20 class, and continued access across commercial and government payers.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Our net product revenue is subject to gross-to-net adjustments, including mandatory government discounts and rebates, contractual rebates and chargebacks, trade discounts and allowances (including cash discounts), product returns, distribution fees, and patient support programs. These adjustments are influenced by payer mix, coverage determinations, contracting dynamics, and patient assistance utilization, and may fluctuate from period to period. As our commercial footprint expands and payer contracting strategies evolve, the magnitude and variability of these adjustments may change.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In addition to the ongoing commercialization of BRIUMVI, we continue to invest in our commercial organization, infrastructure, and internal capabilities to support lifecycle management and potential expansion of the product’s clinical and commercial profile. A key area of focus is the development of a subcutaneous formulation of ublituximab, which is being evaluated as a potential alternative route of administration that may offer increased convenience and flexibility for patients and healthcare providers. We are also exploring the use of BRIUMVI in autoimmune indications outside of MS and are advancing early-stage development activities for azer-cel in autoimmune diseases. These programs reflect our broader strategy to enhance the durability of our portfolio and expand future therapeutic opportunities.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Beyond BRIUMVI, we continue to evaluate potential in-licensing and acquisition opportunities. These opportunities may include earlier-stage programs, complementary products, proprietary technologies, or other therapeutic approaches that could enhance our pipeline and support long-term growth. The scope, timing, and level of any such investments will depend on a range of factors, including scientific and clinical data, manufacturing feasibility, regulatory considerations, commercial readiness, available resources, and overall strategic and financial priorities.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Although we have recently achieved profitability, we have historically incurred substantial operating losses since our inception and may continue to experience fluctuations in operating results. Despite the commercialization of BRIUMVI and the potential future commercialization of other product candidates, there can be no assurance that we will maintain profitability on an ongoing basis.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
For the twelve months ended December 31, 2025, we generated revenue of $616.3 million. Historically, our operating losses have been driven primarily by expenses related to research and development programs and selling, general and administrative costs associated with our operations and commercialization activities to date. Our operating results and cash flows have fluctuated in the past and may continue to vary significantly from period to period. We will need to generate substantial revenues to sustain profitability and positive cash flow over the long term.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
As of December 31, 2025, our accumulated deficit was approximately $1.1 billion, and we had $199.5 million in cash and cash equivalents, and investment securities. Based on our current operating plan and results, we anticipate that our existing cash, cash equivalents, and investment securities, together with projected future revenues, will be sufficient to fund operations and meet our liquidity needs for more than twelve months after the date of issuance of this Annual Report on Form 10-K.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
The actual level of cash required for operations will depend on numerous factors, including, among others, the scope of commercialization activities for BRIUMVI, the timing of collection of receivables from our customers on extended payment terms, the timing and design of clinical trials for our product candidates, and the costs associated with licensing or acquiring new product candidates. We may seek significant additional financing in the future to support strategic initiatives and our ongoing and planned operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
We expect our expenses to increase as we continue to grow and expand our clinical programs and pursue the potential commercialization of additional product candidates. We anticipate incurring significant research and development expenses related to these activities for the foreseeable future. The actual amount of cash needed to support these strategic initiatives will depend on many factors, including:
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedMD&A
In February of 2021, we announced that the FDA granted accelerated approval of umbralisib, the Company’s PI3K delta inhibitor, then commercially referred to as UKONIQ, for the treatment of adult patients with relapsed or refractory MZL who have received at least one prior anti-CD20 based regimen and adult patients with relapsed or refractory FL who have received at least three prior lines of systemic therapy. In April of 2022, we announced the voluntary withdrawal of UKONIQ from sale for the approved indications. Our only source of product revenues during the year ended December 31, 2022 was from the sale of UKONIQ. Our only source of product revenues during the years ended December 31, 2023 and 2024, was from the sale of BRIUMVI. Product revenues are recorded net of estimates of variable consideration. For further discussion of our revenue recognition policy, see “Critical Accounting Policies and Significant Judgements and Estimates” below.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
Our other research and development expenses consist primarily of expenses relating to the design, development, manufacture, testing and enhancement of our drug candidates and technologies, milestone expenses related to in-licensing of new product candidates, fees paid to consultants and outside service providers for clinical and laboratory development, personnel expenses and other facilities-related expenses. We expense our research and development costs as they are incurred. Research and development expenses for the years ended December 31, 2024, 2023 and 2022 were approximately $83.1 million, $63.2 million and $112.1 million respectively, excluding noncash compensation expenses related to research and development.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
(in thousands) 2024 2023 Product revenue, net $ 313,728 $ 92,005 License, milestone, royalty and other revenue 15,276 141,657 Total Revenue $ 329,004 $ 233,662 Costs and expenses: Cost of revenue 38,486 14,131 Research and development: Noncash compensation 11,160 13,010 Other research and development 83,131 63,182 Total research and development 94,291 76,192 Selling, General and administrative: Noncash compensation 31,381 24,923 Other selling, general and administrative 122,917 97,783 Total selling, general and administrative 154,298 122,706 Total costs and expenses 287,075 213,029 Interest expense 24,028 12,615 Other income (7,693) (5,044) Total other expense, net 16,335 7,571 Net income before taxes 25,594 13,062 Income taxes 2,211 390 Net income $ 23,383 $ 12,672
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
(in thousands) 2023 2022 Product revenue, net $ 92,005 $ 2,633 License, milestone and other revenue 141,657 152 Total Revenue $ 233,662 $ 2,785 Costs and expenses: Cost of product revenue 14,131 265 Research and development: Noncash compensation 13,010 13,224 Other research and development 63,182 112,128 Total research and development 76,192 125,352 General and administrative: Noncash compensation 24,923 31,438 Other selling, general and administrative 97,783 64,046 Total general and administrative 122,706 95,484 Total costs and expenses 213,029 221,101 Interest expense 12,615 10,191 Other income (5,044) (4,695) Total other expense, net 7,571 5,496 Net income (loss) before taxes 13,062 (223,812) Income taxes 390 — Net income (loss) $ 12,672 $ (223,812)
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
Historically, we have incurred operating losses since our inception; however, during the year ended December 31, 2024, and December 31, 2023 the Company generated net income. During the year ended December 31, 2023, the Company experienced a net profit due to a $140.0 million non-refundable upfront payment recognized as license revenue in the third quarter of 2023 as part of our Commercialization Agreement with Neuraxpharm (see Note 2 for more information). We may incur operating losses in the near term and may never become profitable. As of December 31, 2024, we have an accumulated deficit of $1.5 billion.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
Our major sources of cash have been proceeds from private placements and public offerings of equity securities, from our loan and security agreements, the upfront payment from the Commercialization Agreement (see Note 2 for more information), and from product revenue from drug sales of BRIUMVI. Substantially all our operating losses have resulted from costs incurred in connection with our research and development programs and from selling, general and administrative costs associated with our operations, including our commercialization activities. As of December 31, 2024, we generated $313.7 million in product revenue from sales of BRIUMVI. BRIUMVI first became commercially available in the United States in January 2023. Even with the commercialization of BRIUMVI and the possible future commercialization of our other drug candidates, we may not realize continued profitability. Our ability to achieve continued profitability depends on our ability to generate revenue and many other factors, including our ability to successfully commercialize our drug candidates alone or in partnership; successfully complete any post-approval regulatory obligations and our ability to maintain or obtain regulatory approval for our drug candidates. We may incur operating losses even now that we are generating revenues from BRIUMVI.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
As of December 31, 2024, we had $311.0 million in cash and cash equivalents, and short-term investment securities. We anticipate that our cash, cash equivalents, and investment securities as of December 31, 2024, combined with projected revenues associated with the sale of BRIUMVI in the U.S. and ex-U.S., will provide sufficient liquidity for more than a twelve-month period from the date of filing this Annual Report on Form 10-K. The actual amount of cash that we will need to operate is subject to many factors, including, but not limited to, our commercialization efforts for BRIUMVI, and the timing, design and conduct of clinical trials for our drug candidates as well as the costs associated with licensing or otherwise acquiring new product candidates. We may be dependent upon significant future financing to provide the cash necessary to execute our ongoing and future operations, including the commercialization of any of our drug candidates.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
During the year ended December 31, 2023, we sold a total of 1,385,700 shares of common stock under the 2022 ATM for aggregate total gross proceeds of approximately $47.1 million at an average selling price of $34.01 per share, resulting in net proceeds of approximately $46.3 million after deducting commissions and other transactions costs.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
The 2022 WKSI Shelf is currently our only active shelf registration statement. We may offer any combination of the securities registered under the 2022 WKSI Shelf from time to time in response to market conditions or other circumstances if we believe such a plan of financing is in the best interests of our stockholders. We may need to file additional shelf registration statements in the future to provide us with the flexibility to raise additional capital to finance our operations as needed.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
On March 31, 2023 (the First Amendment Effective Date), the Company entered into a First Amendment to the Amended and Restated Loan and Security Agreement (the First Amendment) with Hercules Capital, Inc. (Hercules). The First Amendment amended the terms of the Amended and Restated Loan and Security Agreement (Amended Loan Agreement) with Hercules that closed on December 30, 2021. The First Amendment amended the terms of the Amended Loan Agreement to, among other things, (i) issue an advance of $25.0 million drawn at the First Amendment Effective Date (the Tranche 3A Advance), (ii) provide for the formal expiration of Tranche 2, (iii) change the draw amounts and dates available under subsequent tranches, including splitting the remaining balance of Tranche 3 into two additional advances in an aggregate principal amount of up to $20.0 million, in increments of $10.0 million (a Tranche 3B Advance and a Tranche 3C Advance), decreasing the amount available under Tranche 4 from $65.0 million to $60.0 million, and adding a Tranche 5 of $25.0 million, subject to the achievement of revenue related performance milestones, (iv) extend the interest only period from February 1, 2025 to August 1, 2025 and (v) modify the cash interest rate to be the greater of either (a) the “prime rate” as reported in The Wall Street Journal plus 1.20%, and (b) 8.95%. In addition to the cash interest rate, the principal balance will accrue paid-in-kind interest at a rate of 2.25%, which amount will be capitalized and added to the outstanding principal balance of the Amended Term Loan and payable at the maturity date of the Amended Loan Agreement, as amended, The Amended Loan Agreement, as amended, contains financial covenants that require the Company to maintain certain levels of unrestricted cash and additional financial covenants related to market capitalization.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
The Amended Loan Agreement, as amended also contains warrant coverage of 2.95% of the total amount funded. A warrant (the Warrant) was issued by the Company to Hercules to purchase 115,042 shares of common stock with an exercise price of $17.95 for the initial amount funded at the Closing Date. The Warrant shall be exercisable for seven years from the date of issuance. Hercules may exercise the Warrant either by (a) cash or check or (b) through a net issuance conversion. Additionally, a warrant was issued by the Company to Hercules to purchase 50,172 shares of common stock with an exercise price of $14.70 for the amount funded pertaining to the Tranche 3A Advance (the First Amendment Warrant). The First Amendment Warrant shall be exercisable for seven years from the date of issuance. Hercules may exercise the First Amendment Warrant either by (a) cash or check or (b) through a net issuance conversion.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RemovedMD&A
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting—Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about segment expenses categorized as significant or regularly provided to the Chief Operating Decision Maker (CODM). The amendments in ASU No. 2023-07 apply to public entities, including those with a single reportable segment, and are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company has evaluated the impact ASU No. 2023-07 on its consolidated financial statements. The Company has adopted this standard as of December 31, 2024 and noted there was no material impact on the Company's consolidated financial statements. The adoption did result in enhanced disclosures as included in Note 1 - Organization and Summary of Significant Accounting Policies.
Read it in 10-K Mar 3, 2025 at sec.govopen_in_new
RewordedMD&A
The increase in other research and development expense during the year ended December 31, 2024 was primarily attributable due to an increase in manufacturing expense, including manufacturing and development costs incurred in connection with our subcutaneous ublituximab subcutaneous development work, increased clinical trial related expenses pertaining to our clinical pipeline, and increased personnel and costs associated with the Precision License Agreement incurred during the period. period ended December 31, 2025, as compared to the year ended December 31, 2024.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Based on In accordance with our policy to expense costs associated with the manufacture of our products prior to regulatory approval, a portion of the manufacturing costs of incurred to produce BRIUMVI units recognized as revenue during the years ended before its FDA approval in December 31, 2023 and 2024 2022 were expensed prior to receipt of FDA approval on December 28, 2022, research and therefore are not included in costs of product revenue during those periods. development.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Based on our policy to expense costs associated with the manufacture of our products prior to regulatory approval, As a result, a portion of the manufacturing costs of BRIUMVI units recognized as revenue during the years ended December 31, 2025, 2024 and 2023 and 2024 were expensed prior to receipt of FDA approval on December 28, 2022, and therefore are not included in costs the cost of product revenue during those periods.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Food and Drug Administration (FDA) for BRIUMVI® BRIUMVI (ublituximab-xiiy) for the treatment of to treat adult patients with relapsing forms of multiple sclerosis (RMS), to include including clinically isolated syndrome, relapsing-remitting disease disease, and active secondary progressive disease, in adults, as well as approval by from several regulatory agencies outside of the European Commission (EC) and the Medicines and Healthcare products Regulatory Agency (MHRA) U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom (UK), respectively. features.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The decrease increase in noncash compensation expense was primarily due to decreased vesting greater recognition of milestone-based grants noncash compensation expense for performance-based awards and the grant-date fair value of equity awards, including the impact of our increased stock price at which equity awards were granted, during the year ended December 31, 2024, 2025, as compared to the year ended December 31, 2023. 2024.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
License, milestone, royalty and other revenue for the year ended December 31, 2023 2025 is predominantly comprised of recognition $3.8 million consideration received for development and regulatory activities performed on behalf of Neuraxpharm in accordance with the one-time $140.0 Commercialization Agreement and $5.6 million non-refundable upfront payment of royalty revenue recognized under the Commercialization Agreement with Neuraxpharm (see Note 2 - Revenue for more information).
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
In connection with The at-the-market program established under our prior shelf registration statement on Form S-3 pursuant to the 2022 WKSI Shelf, we entered into an At-the-Market Issuance Sales Agreement (the 2022 ATM) Agreement, dated September 2, 2022, with Cantor Fitzgerald & Co. and B.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The increase Net cash used in net cash provided by financing activities during the year ended December 31, 2024 2025 is mainly due to the proceeds from the new loan with Blue Owl, offset by the payoff repurchase of stock under our prior loan with Hercules. share repurchase program.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
On September 2, 2022, August 8, 2025, we filed an automatic “shelf registration” statement on Form S-3 (the 2022 2025 WKSI Shelf) as a “well-known seasoned issuer” WKSI as defined in Rule 405 under the Securities Act, which registered an unlimited and indeterminate amount Act of debt or equity securities for future issuance and sale. 1933, as amended.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
License, milestone, royalty and other revenue for the year ended December 31, 2024 is predominately comprised of a the recognition of the one-time $12.5 million milestone payment under the Neuraxpharm Commercialization Agreement for the first key market commercial launch of BRIUMVI in the EU, as well as consideration received for development and regulatory activities performed on behalf of Neuraxpharm in accordance with the Commercialization Agreement. EU.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The applicable margin for borrowings of the Initial Term Loan is determined on a quarterly basis by reference to a pricing grid based on the achievement of US Net Sales (as defined in the Financing Agreement) for the most recently completed four consecutive fiscal quarters of the Company and its Subsidiaries (as defined in the Financing Agreement). U.S.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in noncash compensation expense was primarily due to greater recognition of noncash compensation expense for grants to executives performance and market-based equity awards, growth in headcount, and higher grant-date stock prices associated with equity awards granted during the year ended December 31, 2025, as compared to the year ended December 31, 2024.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new